Tebideutorexant

Tebideutorexant
Clinical data
Other namesJNJ-61393215; JNJ-3215
Routes of
administration		Oral
Drug classOrexin receptor antagonist
Identifiers
  • [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H18F4N4O2
Molar mass458.417 g·mol−1
3D model (JSmol)
  • [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
  • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
  • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

Tebideutorexant[1] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[2][3][4][5] It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[3][4][5] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.[3][4] As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders.[2] The drug was originated and developed by Janssen Pharmaceuticals.[2]

  1. ^ PubChem. "Tebideutorexant". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
  2. ^ a b c "JNJ 61393215 - AdisInsight".
  3. ^ a b c Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". J Exp Pharmacol. 13: 441–459. doi:10.2147/JEP.S261403. PMC 8055642. PMID 33889031.
  4. ^ a b c Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499. S2CID 248119793.
  5. ^ a b Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, Lebold TP, Nepomuceno D, Dugovic C, Brooks S, Zuiker R, Bleys C, Tatikola K, Remmerie B, Jacobs GE, Schruers K, Moyer J, Nash A, Van Nueten LG, Drevets WC (September 2020). "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Transl Psychiatry. 10 (1): 308. doi:10.1038/s41398-020-00937-9. PMC 7477545. PMID 32895369.